PRF Technologies vs Virax Biolabs
PRFX and VRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PRFX and VRAX compare
PRF Technologies keeps more of each dollar of sales as profit, with a net margin of −29541% compared with −40439% at Virax Biolabs.
Virax Biolabs scores higher on the StockData Score (9 against 6 for PRF Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PRFX | VRAX |
|---|---|---|
| Size and price | ||
| Share price | $0.783 | $0.613 |
| Change, 1 year | −83.8% | −94.7% |
| Change, 5 years | −99.9% | – |
| Beta (5Y) | 1.61 | 1.61 |
| Employees | 6 | – |
| StockData Score | ||
| Total score | 6 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 3 (better) |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | – | 96.2% |
| Revenue growth, 5Y average | – | −36.9% |
| Profitability | ||
| Gross margin | −312% | 61.9% (better) |
| Operating margin | −30129% (better) | −51515% |
| Net margin | −29541% (better) | −40439% |
| FCF margin | −23277% (better) | −39264% |
| Return on equity | −41.3% (better) | −75.7% |
| Return on invested capital | −87.0% (better) | −388% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.07 | 9.97 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Ownership | ||
| Held by institutions | 24.5% | 0.00% |
| Held by insiders | 24.1% | 63.6% |
| Short interest, % of float | 2.0% | 3.2% |
Go deeper
- PRFX stock overview
- PRFX income statement
- PRFX valuation and score
- VRAX stock overview
- VRAX income statement
- VRAX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.